Colorectal Cancer Deaths Surge Among Young Americans as Awareness Campaign Returns

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

Colorectal cancer deaths surge among Americans under 50, becoming the leading cancer killer in this age group. An awareness campaign installs 27,000 blue flags on the National Mall.

Colorectal Cancer Deaths Surge Among Young Americans as Awareness Campaign Returns

Fight Colorectal Cancer will install its fifth annual United in Blue monument on the National Mall from March 1-14, 2026, as the organization highlights a growing public health concern. The installation will feature over 27,000 blue flags, each representing an individual under age 50 projected to receive a colorectal cancer diagnosis in 2030, underscoring the scale of the disease's impact on younger demographics.

The campaign arrives amid new research from the American Cancer Society documenting a significant shift in cancer mortality trends. Colorectal cancer has emerged as the leading cancer killer among Americans under 50, surpassing previous leading causes. Mortality rates within this age group increased in 2025, marking a troubling acceleration in a trend that has prompted increased scrutiny from public health officials and medical organizations.

The visible installation on the National Mall serves as both a public awareness effort and a call to action regarding early detection and prevention strategies. The timing of the campaign reflects the growing urgency within the medical and nonprofit sectors to address colorectal cancer incidence in younger populations, a demographic shift that has prompted renewed attention to screening recommendations and risk factors specific to this age group.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 27

Related Coverage

GlobeNewswire Inc.

Valneva Plunges 37% After Lyme Vaccine Fails Phase 3 Trial; Law Firm Launches Investigation

Valneva stock plummets 37% after Phase 3 Lyme vaccine candidate fails trial; law firm investigates potential securities fraud claims.

PFEVALN
The Motley Fool

Healthcare's Dividend Gems: Why $ABBV and $BMY Stand Out for Income Investors

$ABBV and $BMY deliver above-average dividend yields and growth, standing out as rare healthcare sector exceptions for patient income investors navigating patent cliffs through innovation.

BMYCELGrABBV
GlobeNewswire Inc.

Quotient Therapeutics Lands $2.2B Merck Deal for IBD Drug Discovery Platform

Quotient Therapeutics and Merck partner on IBD drug discovery, with Quotient receiving $20M upfront and up to $2.2B in milestones.

MRK
GlobeNewswire Inc.

Serina Therapeutics to Showcase POZ Platform at Roth Conference

Clinical-stage biotech **Serina Therapeutics** will present at 38th Annual Roth Conference on March 24, 2026, highlighting its proprietary POZ Platform technology and pipeline.

PFESER
The Motley Fool

BMY's 4.4% Dividend Masks Looming Patent Cliff Risks

Bristol Myers Squibb's attractive 4.4% dividend yield faces headwinds from major patent expirations on blockbuster drugs Eliquis and Opdivo.

BMYCELGr
Benzinga

Lyme Vaccine Setback: Valneva-Pfizer Trial Misses Primary Goal But Eyes Regulatory Path

Valneva-Pfizer Lyme vaccine trial misses primary endpoint but shows 73-75% secondary efficacy; Pfizer to seek regulatory approval despite setback. Valneva shares fell 35.27%.

PFEVALN